Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free RCKTW Stock Alerts

Rocket Pharmaceuticals (RCKTW) Competitors

Rocket Pharmaceuticals logo
$0.0007 0.00 (0.00%)
As of 08/28/2026 01:56 PM Eastern
Compare

RCKTW vs. ALVOW, APLMW, ARAV, BIAFW, and BIVIW

Should you buy Rocket Pharmaceuticals stock or one of its competitors? Rocket Pharmaceuticals's main competitors and comparable companies include Alvotech (ALVOW), Apollomics (APLMW), Aravive (ARAV), bioAffinity Technologies (BIAFW), and BioVie (BIVIW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Rocket Pharmaceuticals compare to Alvotech?

Rocket Pharmaceuticals (NASDAQ:RCKTW) and Alvotech (NASDAQ:ALVOW) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

In the previous week, Alvotech had 2 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 3 mentions for Alvotech and 1 mentions for Rocket Pharmaceuticals. Rocket Pharmaceuticals' average media sentiment score of 1.89 beat Alvotech's score of 0.38 indicating that Rocket Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Rocket Pharmaceuticals Very Positive
Alvotech Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rocket PharmaceuticalsN/AN/AN/AN/AN/A
Alvotech$491.95MN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Rocket PharmaceuticalsN/A N/A N/A
Alvotech N/A N/A N/A

Summary

Alvotech beats Rocket Pharmaceuticals on 2 of the 3 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to Apollomics?

Apollomics (NASDAQ:APLMW) and Rocket Pharmaceuticals (NASDAQ:RCKTW) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apollomics$8.50MN/AN/AN/AN/A
Rocket PharmaceuticalsN/AN/AN/AN/AN/A

In the previous week, Apollomics and Apollomics both had 1 articles in the media. Rocket Pharmaceuticals' average media sentiment score of 1.89 beat Apollomics' score of 1.87 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Apollomics Very Positive
Rocket Pharmaceuticals Very Positive

Company Net Margins Return on Equity Return on Assets
ApollomicsN/A N/A N/A
Rocket Pharmaceuticals N/A N/A N/A

Summary

Apollomics and Rocket Pharmaceuticals tied by winning 1 of the 2 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to Aravive?

Rocket Pharmaceuticals (NASDAQ:RCKTW) and Aravive (NASDAQ:ARAV) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Company Net Margins Return on Equity Return on Assets
Rocket PharmaceuticalsN/A N/A N/A
Aravive N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rocket PharmaceuticalsN/AN/AN/AN/AN/A
AraviveN/AN/AN/A-$0.90N/A

35.8% of Aravive shares are owned by institutional investors. 60.4% of Aravive shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Rocket Pharmaceuticals had 1 more articles in the media than Aravive. MarketBeat recorded 1 mentions for Rocket Pharmaceuticals and 0 mentions for Aravive. Rocket Pharmaceuticals' average media sentiment score of 1.89 beat Aravive's score of 0.00 indicating that Rocket Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Rocket Pharmaceuticals Very Positive
Aravive Neutral

Summary

Rocket Pharmaceuticals and Aravive tied by winning 2 of the 4 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to bioAffinity Technologies?

bioAffinity Technologies (NASDAQ:BIAFW) and Rocket Pharmaceuticals (NASDAQ:RCKTW) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Company Net Margins Return on Equity Return on Assets
bioAffinity TechnologiesN/A N/A N/A
Rocket Pharmaceuticals N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
bioAffinity Technologies$5.85MN/AN/AN/AN/A
Rocket PharmaceuticalsN/AN/AN/AN/AN/A

In the previous week, bioAffinity Technologies had 2 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 3 mentions for bioAffinity Technologies and 1 mentions for Rocket Pharmaceuticals. Rocket Pharmaceuticals' average media sentiment score of 1.89 beat bioAffinity Technologies' score of 0.30 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
bioAffinity Technologies Neutral
Rocket Pharmaceuticals Very Positive

Summary

bioAffinity Technologies beats Rocket Pharmaceuticals on 2 of the 3 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to BioVie?

BioVie (NASDAQ:BIVIW) and Rocket Pharmaceuticals (NASDAQ:RCKTW) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

In the previous week, BioVie had 1 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 2 mentions for BioVie and 1 mentions for Rocket Pharmaceuticals. Rocket Pharmaceuticals' average media sentiment score of 1.89 beat BioVie's score of 0.43 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
BioVie Neutral
Rocket Pharmaceuticals Very Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioVieN/AN/AN/AN/AN/A
Rocket PharmaceuticalsN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
BioVieN/A N/A N/A
Rocket Pharmaceuticals N/A N/A N/A

Summary

BioVie and Rocket Pharmaceuticals tied by winning 1 of the 2 factors compared between the two stocks.

Get Rocket Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for RCKTW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RCKTW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RCKTW vs. The Competition

Export
MetricRocket PharmaceuticalsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$3.94B$7.18B$12.89B
Dividend YieldN/A3.61%2.54%11.28%
P/E RatioN/A11.68273.1725.45
Price / SalesN/A1,408.83638.19104.21
Price / CashN/A44.0628.7436.03
Price / BookN/A16.9211.086.36
Net IncomeN/A-$22.74M$3.48B$349.79M
7 Day PerformanceN/A-0.13%0.38%-0.40%
1 Month PerformanceN/A11.45%7.89%4.24%
1 Year PerformanceN/A55.66%24.71%15.13%

Rocket Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RCKTW
Rocket Pharmaceuticals
N/A$0.00
flat		N/A-98.2%$0.00N/AN/A240
ALVOW
Alvotech
N/A$0.22
flat		N/AN/A$0.00$491.95MN/A4
APLMW
Apollomics
N/A$0.01
flat		N/A+79.5%$0.00$8.50MN/A59
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
BIAFW
bioAffinity Technologies
N/A$0.12
+2.1%		N/AN/A$0.00$5.85MN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:RCKTW) was last updated on 8/31/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel